Cancers · 2021 · 12 citations · 27 references
MedicineOncologyImmunotherapyMetastasisNeuro-oncologyBrain MetastasesBrain MetastasisCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsMetastatic Brain TumorsBrain Metastasis Systemic TherapyImmune Checkpoint ResistanceMek InhibitorsMelanoma ImmunotherapyMetastatic Melanoma TreatmentResistance To Checkpoint InhibitorsTreatment Strategies
Brain metastases commonly develop in melanoma and are associated with poor overall survival of about five to nine months. Fortunately, new therapies, including immune checkpoint inhibitors and BRAF/MEK inhibitors, have been developed. The aim of this study was to identify outcomes of different treatment strategies in patients with melanoma brain metastases in the era of checkpoint inhibitors. Patients with brain metastases secondary to melanoma were identified at a single institution. Univariate and multivariable analyses were performed to identify baseline and treatment factors, which correlated with progression-free and overall survival. A total of 209 patients with melanoma brain metastases were identified. The median overall survival of the cohort was 5.3 months. On multivariable analysis, the presence of non-cranial metastatic disease, poor performance status (ECOG 2-4), whole-brain radiation therapy, and older age at diagnosis of brain metastasis were associated with poorer overall survival. Craniotomy (HR 0.66, 95% CI 0.45-0.97) and treatment with a CTLA-4 checkpoint inhibitor (HR 0.55, 95% CI 0.32-0.94) were the only interventions associated with improved overall survival. Further studies with novel agents are needed to extend lifespan in patients with brain metastases in melanoma.
27
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi, Peter Forsyth, Alain P. Algazi et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text
Paul D. Brown, Karla V. Ballman, Jane H. Cerhan et al. · The Lancet Oncology · 2017 · 1.2K citations · Full text